Join Growin Stock Community!

Ernexa therapeutics inc.ERNA.US Overview

US StockHealthcare
(No presentation for ERNA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ERNA AI Insights

ERNA Overall Performance

ERNA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ERNA Recent Performance

3.40%

Ernexa therapeutics inc.

0.05%

Avg of Sector

-0.31%

S&P500

ERNA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ERNA Key Information

ERNA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ERNA Profile

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Price of ERNA

ERNA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ERNA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.34
PE Ratio (TTM)
0.01
Forward PE
-
PS Ratio (TTM)
7721.97
PB Ratio
2.22
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1834000.00%
Revenue Growth (YoY)
-99.83%
Profit Growth (YoY)
-99.77%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.34
PE Ratio (TTM)
0.01
Forward PE
-
PS Ratio (TTM)
7721.97
PB Ratio
2.22
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1834000.00%
Revenue Growth (YoY)
-99.83%
Profit Growth (YoY)
-99.77%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ERNA's latest earnings report released?

    The most recent financial report for Ernexa therapeutics inc. (ERNA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ERNA's short-term business performance and financial health. For the latest updates on ERNA's earnings releases, visit this page regularly.

  • How is ERNA's revenue growth?

    In the latest financial report, Ernexa therapeutics inc. (ERNA) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ERNA have?

    As of the end of the reporting period, Ernexa therapeutics inc. (ERNA) had total debt of 552K, with a debt ratio of 0.09. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ERNA have?

    At the end of the period, Ernexa therapeutics inc. (ERNA) held Total Cash and Cash Equivalents of 3.05M, accounting for 0.49 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ERNA's EPS continuing to grow?

    According to the past four quarterly reports, Ernexa therapeutics inc. (ERNA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.15. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ERNA?

    Ernexa therapeutics inc. (ERNA)'s Free Cash Flow (FCF) for the period is -1.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 79.47% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ERNA?

    The latest valuation data shows Ernexa therapeutics inc. (ERNA) has a Price-To-Earnings (PE) ratio of -0.75 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.